MindRank Announces Initiation of Phase III Clinical Trial for AI-Designed Oral Small Molecule GLP-1 Receptor Agonist MDR-001 in China

On June 19, 2025, medication was administered to 317 subjects (baseline weight of 90KG).24 WeeksClinical AfterResults of Phase IIb Trial Announced, Strongly Validating MDR-001's Core Differentiation Advantages:

• Significant efficacy：Weight decreased by 10.3% after 24 weeks of treatment.

• Good safety:AdoptA rapid titration dosing strategy of around 8 weeks. During the trial periodNo drug-related serious adverse events (SAE）。Due to adverse events (TEAE) leading to treatment discontinuation was only0.8%；No risk of increased heart rate was observed throughout the trial.

• Comprehensive Improvement in Cardiovascular Metabolism:Liver indicators, waist circumference, blood pressure, blood lipids,HbA1c, fasting blood glucose, and multiple other indicators showed improvement. At the same time, a significant reduction in uric acid levels of up to 57.7µmol/L (P<.00001) was achieved, along with notable improvements in several transaminase indicators. Despite including approximately 20% of subjects with previously abnormal liver function and elevated transaminase levels, the transaminase indicators significantly improved from baseline (with the ALT indicator in the high-dose group decreasing by nearly 40%).

SelfSince 2021, with the support of the artificial intelligence platform Molecule Pro, MindRank has built more than 10 self-developed pipelines and nominated 7 clinical candidate compounds, two of which have received clinical trial approvals. Meanwhile, in recent years, the company has published dozens of peer-reviewed papers with industry influence, some of which have been featured in Nature, Cell, and Science journals.

Regarding the Phase III Clinical Trial MOBILE

The Phase III trial MOBILE for MDR-001 is a multicenter, randomized, double-blind, placebo-controlled study, planning to enroll participants who are obese (BMI≥28.0 kg/㎡) or overweight (24.0 kg/㎡≤BMI＜28.0 kg/㎡) and have at least one weight-related comorbidity, the primary endpoint of the study isThe percentage of weight loss from baseline at 52 weeks and the proportion of participants achieving ≥5% weight reduction are primary endpoints. Secondary endpoints include changes in waist circumference, blood lipids, blood pressure, blood glucose, quality of life scales, and inflammatory markers from baseline, along with a comprehensive evaluation of the long-term safety of the medication. The MOBILE study is led by Professor Linong Ji, Director of the Endocrinology Department at Peking University People's Hospital.

AboutMDR-001

MDR-001 was developed by the expert team at MindRank using the PharmKG™ biology knowledge graph, integrating extensive literature and biological pathway analysis. Relying on Molecule Dance™ protein dynamic simulation modeling and iterative biological validation, it provides an in-depth analysis of GPCR protein-small molecule binding conformations and signal transduction mechanisms, quantifying the specific activity of relevant biological pathways, including cAMP activation and β-arrestin1/β-arrestin2 recruitment, thereby guiding the design of highly selective biased GLP-1RA small molecules. Using the generative AI and ADMET prediction modules of the Molecule Pro™ platform alongside iterative wet-lab feedback, systematic prediction and optimization of the drug-like properties and safety of small-molecule candidates based on structural features were achieved.

AboutMolecule Pro

MoleculeProMindRank's self-developed AI-driven drug discovery platform, which deeply integrates professional technologies from the fields of artificial intelligence, computational chemistry, chemistry, biology, and medicine, with deep learning and generative...AI and large models are the core drivers. The platform integrates nearly a hundred original algorithm models, among which core modules such as large language model knowledge graphs and ADMET prediction have reached internationally leading levels. Molecule Pro focuses on the drug development scenarios for difficult-to-drug targets, adopting a multi-objective optimization strategy to synergistically balance activity, selectivity, pharmacokinetics, and safety. By introducing predictive mechanisms for toxicity and off-target risks, it avoids groups that may cause adverse reactions (such as structural fragments that cause liver damage), precisely designs and optimizes molecules, thereby systematically improving the efficiency and success rate of drug research and development.

About MindRank

MindRank is aAn AI-driven biotech company dedicated to advancing AI for Science in the field of new drug discovery and leading paradigm shifts. Leveraging an AI platform that deeply integrates biology, structural biology, chemistry, and medicine, the company focuses on tackling "undruggable" targets, enhancing the efficiency and success rate of new drug discovery, with the aim of providing innovative therapies with greater clinical benefits for patients worldwide.